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Abstract 
The objective of this study was to investigate the preventive effects of rosemary leaf extract (RE) 
and its active components on prevention of weight gain and associated metabolic disorders in 
high-fat-fed mice; determine the effective doses of the chief compound in RE to reduce weight 
gain and hyperglycemia; and try to understand the underlying anti-obesity mechanism. For this 
purpose, commercial RE with 45% carnosic acid (CA) was enriched with CA to 80%. Animals 
were given low-fat diet (LFD), high-fat diet (HFD), high fat with 0.50% RE (enriched with 45% 
CA, RE#1), high fat with 0.28% w/w RE (enriched with 80% CA, RE#2H), and high fat with 
0.14% w/w RE (enriched with 80% CA, RE#2L) for 16-week periods. Physiological and 
biochemical parameters were monitored. Treatment with CA, dose dependently, induced a 
significant reduction of weight and fat mass gain which it was associated with an increase of 
fecal lipid excretion. Likewise, hypercholesterolemia, fasting glycaemia, and insulin resistant 
were improved by CA treatments. Hepatic triglyceride levels, correspondingly, were decreased 
in CA-treated mice. In conclusion, the results from this study demonstrate that consumption of 
the RE that is rich in CA, dose dependently can limit weight gain induced by a high-fat diet and 
protect against obesity-related metabolic disorders. 
2 
CHAPTER 1 
Introduction 
Metabolic syndrome is a global emerging health concern. Endocrine and metabolic 
diseases are problematic modern human disorders, primarily in the United States and other 
countries with extensive nutrition. Their risk factors have capability of acting as an indicator 
for many chronic diseases such as cardiovascular disease, kidney disease, and type 2 diabetes 
mellitus (Woolston, Tu, Baxter, & Gilthorpe, 2012). Effective strategy against obesity and 
hyperglycemia, two important risk factors of metabolic syndrome, is critical for reducing the 
possibility of cardiovascular disease. Side effects of the currently existing methods such as 
pharmacological and surgical interventions have impeded their usefulness. This awareness has 
led to nonstop effort to discover effective agents such as new medications as well as natural 
products extracted from herbal plants. Many active compounds extracted from herbal plants 
possess healing values, i.e. antiobesity and hypoglycemic activity, etc.(Joyal, 2004).  Using 
botanicals provides safer pharmaceutical and nutritious products for customers and less 
expensive approval process under the guidelines of  to the US Food and Drug Administration 
(M. Romo Vaquero et al., 2012). 
Therefore, the present research has been performed to investigate effects of REs and 
their major active component CA, dose dependently, in high-fat-fed mice. 
1.1 Metabolic Syndrome and Obesity 
Metabolic syndrome is a combination of conditions related to obesity that includes 
excess central adiposity, insulin resistance, hyperlipidemia, and hypertension. The syndrome 
may affect more than 5% of the elderly in the United States and even higher percentages in 
different racial groups around the world (Golden, Robinson, Saldanha, Anton, & Ladenson, 
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2009). A rapid increase in metabolic syndrome prevalence and severity has paralleled the 
dramatic increase in rates of obesity and type 2 diabetes (F. M. Elisa Fabbrini, B. Selma 
Mohammed, Terri Pietka, Nada A. Abumrad, Bruce W. Patterson, Adewole Okunade, Samuel 
Klein, 2009). 
Metabolic syndrome profoundly affects the quality of life and represents a life-long 
burden on a patient’s social support system. To the extent that the component risk factors of the 
metabolic syndrome contribute to cardiovascular disease with long time treatment, the financial 
impact on the Medicare program may be substantial. Alyssa et al. estimated that people with 
metabolic syndrome cost $259 more per month than those comparable individuals without the 
syndrome (Alyssa B. Schultz., 2009). Meanwhile another research showed the medical costs are 
20% higher rates among patients with the metabolic syndrome than among those without in 10 
years (Curtis et al., 2007). The unsustainable growth in health care spending in the United States 
increases importance of prevention investment. However, costs to the society related to excess 
metabolic disorders, component risk factors, and their complications are not limited to health 
care costs. Losses attributable to reduced job productivity such as absenteeism, disability, labor 
productivity reduction, have also been found to be associated with these health risks. Studies 
suggest that the costs of lost productivity from metabolic syndrome and its complications could 
far go above the costs of medical care (Schultz AB, 2009). 
Today, obesity is a global concern because of its fast growing rates and its comorbidities, 
such as type 2 diabetes and cardiovascular disease. In addition, obesity is also associated with 
increased risk of various cancers, including endometrial, breast, and colon cancer (Strain et al., 
2012). It has been predicted that obesity will be the number one health problem globally by the 
4 
year 2025 and thought to be overtaking cigarette smoking soon to become the leading cause of 
death in the United States. 
1.2 Adipose Tissue and Obesity 
Obesity is related to an abnormal large amount of body fat, specifically adipose tissue. 
The major component of adipose tissue, adipocyte, plays an important role as an energy storage 
site in the form of triglyceride (Brännmark et al., 2013). Adipose tissue maintains the free fatty 
acid levels and triglycerides in circulation. It has been demonstrated that an amplified amount of 
adipose tissue related to obesity is caused by  increase in the number of adipocytes, hyperplasia, 
or by increase in the size of adipocyte which it is called hypertrophy (Wolfram, Wang, & 
Thielecke, 2006). 
Visceral adipose tissue is around the internal organs and releases free fatty acids and 
adipokines into the portal vein for direct transport to the liver. This role makes visceral adipose 
tissue count as an important and independent predictor of metabolic risk factors for coronary 
heart disease, particularly diabetes and dyslipidemia (F. M. Elisa Fabbrini, B. Selma 
Mohammed, Terri Pietka, Nada A. Abumrad, Bruce W. Patterson, Adewole Okunade, Samuel 
Klein, 2009; S. S. Elisa Fabbrini, Samuel Klein, 2010). Moreover, the results from a study on 
human subjects with metabolic syndrome demonstrated  that an increase in visceral adipose 
tissue is associated with glucose tolerance reduction, insulin resistance, and increased very-low-
density lipoprotein– triglyceride secretion (Adiels et al., 2006). These findings, have led to the 
thought that visceral adipose tissue is in charge for many of the metabolic defects associated with 
abdominal obesity (Bays, Blonde, & Rosenson, 2006). In conclusion, a reduction in visceral fat 
has become a key therapeutic goal in the controlling of obesity and metabolic syndrome. 
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1.3 Dietary Prevention of Weight Gain and Metabolic Syndrome by Rosemary and 
Rosemary Constituents 
In the last decade, nutritional, pharmacological, and surgical strategies have been 
developed to prevent the metabolic effect of high fat diet. According to the adverse side effect of 
the pharmacological and surgical intervention, nutritional intervention maybe is the safest and 
most cost effective option for those who have moderate metabolic syndrome. Hence, nutritional 
intervention, in particular the use of herbs in the prevention of metabolic syndrome and its 
complications has been growing tremendously during these years. 
Rosemary (Rosmarinus officinalis) is an herb widely used in the flavoring of food, folk 
medicine, cosmetics, and phytopharmacy. Previous studies have revealed that the biological 
activities of rosemary (Rosmarinus officinalis L.) are credited to its components such as CA, 
carnosol, rosmarinic acid, and ursolic acid content (Debersac, Vernevaut, Amiot, Suschetet, & 
Siess, 2001; Del Campo, Amiot, & Nguyen-The, 2000; Ibarra et al., 2011; Karpinska, Borowski, 
& Danowska-Oziewicz, 2000; Koga, Nomoto, Shibata, & Yoshino, 2006; Kosaka & Yokoi, 
2003; Lo, Liang, Lin-Shiau, Ho, & Lin, 2002; Moreno, Scheyer, Romano, & Vojnov, 2006; 
Moss, Cook, Wesnes, & Duckett, 2003; Naemura, Ura, Yamashita, Arai, & Yamamoto, 2008; 
Pengelly et al., 2012; Perez-Fons, Garzon, & Micol, 2010; Steiner et al., 2001; Takahashi et al., 
2009). One of the most interesting food additive compound in rosemary is CA through it strong 
antioxidant effect. CA is an abietane diterpene found in the popular Labiatae herbs sage and 
rosemary and it is considered as an originator of other diterpenoid constituents in the herbs. 
Many studies have determined the antioxidant activities of CA and related diterpenes such as 
carnosol and rosmanol. The results have shown CA has the most powerful antioxidant power 
among these diterpenes. Easily oxidization of CA has been related to its typical o- diphenol 
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structure (Bozin, Mimica-Dukic, Samojlik, & Jovin, 2007; Jordan, Lax, Rota, Loran, & 
Sotomayor, 2012; Masuda et al., 2002; Moreno et al., 2006). 
 CA has a good safety profile which does not pose a health concern for the European 
Food Safety Authority (European Food Safety Authority, 2008). The Panel notes that the margin 
between the not observable adverse effect level of carnosol plus CA, as calculated in 90 days rat 
studies, is equivalent to 20–60 mg/Kg body weight (mpk), and the mean intake of CA rich REs is 
estimated to be 500–1500 mg/day in adults and 182–546 mg/day in pre-school children 
(European Food Safety Authority, 2008). It is assumed that at the concentrations are used as a 
food additive, CA levels would not cause significant hepatotoxicity. There are couple in vivo 
researches studies have been published for evaluating weight loss and antiadipogenic effects with 
different doses of CA. Even the capacities of rosemary to control obesity and hyperglycemia 
have been observed in vivo, whether these effects are due to CA or other constituents is currently 
unknown. Moreover, little is known about the safety, and the mechanisms of CA at doses that are 
needed to achieve therapeutic effect for weight loss and control hyperglycemia. It is important to 
identify the major active compound in rosemary, and to confirm its efficacy and safety in 
relevant biological models before conducting clinical trial research. 
1.4 Specific Aims and Central Hypothesis of the Research 
The prevalence of metabolic syndrome is dramatically increased in developing and 
industrialized countries (Miranda, DeFronzo, Califf, & Guyton, 2005). Excess metabolic 
disorders, component risk factors, and their complications affect the  health care costs and also to 
the social productivity (Alyssa B. Schultz., 2009). Obesity is reaching epidemic and an 
established risk factor for various comorbidities, such as type 2 diabetes, metabolic disorders and 
cardiovascular disease worldwide (Golden, Robinson, Saldanha, Anton, & Ladenson, 2009). 
7 
Although, Rosemary (Rosmarinus officinalis L.) extracts is shown to be an effective treatment to 
prevent the metabolic effect of high fat diet (Ibarra et al., 2011), it is not fully understood 
whether the antiobesity and antidiabetic effect is due to CA or other active components. 
Moreover, the mechanisms of action and effective therapeutic doses for its active components 
are also unclear. 
Our long-term goal is to develop rosemary and its active components as a safe and 
effective approach for high-fat diet-induced metabolic syndrome. The objectives of this study 
were to identify the economic way to prepare CA enriched RE from the commercial RE (45% 
CA), and determine the preventive effects of RE (45% CA), and its active compound on weight 
gain, glucose levels and lipid homeostasis in high-fat-fed mice; identify the effective doses of the 
active component and RE to reduce weight gain and type 2 diabetes; and understand the 
underlying mechanisms. These studies provided useful information as to the effective doses of 
CA enriched RE on the risk for chronic disease, and they were also served as foundation for 
understanding the important mechanisms by which CA may help prevent this disease. 
 Central hypothesis: The central hypothesis was that CA as the major active component 
of rosemary can dose dependently prevent the development of metabolic syndrome induced by 
high fat diet. 
We expected to test our hypothesis by pursuing the following three specific aims: 
1. To determine whether CA is the major active component in RE.
2. Investigate the dose depending effects of dietary CA enriched RE on high fat diet
induced metabolic syndrome. 
3. Investigate the underlying fat limiting mechanisms of RE and CA.
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CHAPTER 2 
Literature Review 
2.1 Obesity, Type 2 Diabetes, and Metabolic Syndrome 
 Obesity is a health condition that is characterized by a body mass index (BMI), 30 or 
higher which  is associated to an abnormal large amount of body fat, specifically adipose tissue 
(J. James, 2004). The rates of obesity have increased dramatically in the United States in the last 
20 years and even more rapidly in the last 10 years. The studies have shown consumption of a 
high fat diet and sedentary lifestyle lead to obesity. Numerous studies in the last 50 years have 
suggested a significant relation between obesity and the incidence of diseases such as type 2 
diabetes, cardiovascular disease, and hypertension (W. P. James, Rigby, & Leach, 2006). 
However the mechanism(s) responsible for the interrelationship among obesity, insulin 
resistance, and hypertriglyceridemia is not fully known. 
A study by Fabbrini et.al demonstrated that obesity reflected as an increased storage of 
triacylglycerides in adipose tissues (S. S. Elisa Fabbrini, Samuel Klein, 2010). Their data show 
that increased visceral adipose tissue and intrahepatic triglyceride level are important risk factors 
for the metabolic complications associated with obesity, particularly insulin resistance and 
dyslipidemia. There is ample evidence that an impaired non-esterified fatty acid metabolism 
could contribute to the insulin-resistant state observed among individuals with visceral obesity 
(Despres & Lemieux, 2006). Moreover, modifications in tissue fatty acid transport could be 
involved in the pathogenesis of ectopic triglyceride accumulation by redirecting plasma fatty 
acid uptake from adipose tissue toward other tissues (F. M. Elisa Fabbrini, B. Selma 
Mohammed, Terri Pietka, Nada A. Abumrad, Bruce W. Patterson, Adewole Okunade, Samuel 
Klein, 2009). 
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Obesity is considered as one of the primary risk factors for type 2 diabetes in many 
studies.  It has been demonstrated that obesity is often accompanied by chronic, low-grade 
inflammation that is characterized by increased release of inflammatory cytokines such as tumor 
necrosis factor alpha (TNF-α), monocyte chemotactic protein-1 (MCP-1) and adiponectin in 
blood and accumulation of macrophages in the adipose tissue and the liver (Curat et al., 2006; 
Kawano & Arora, 2009; Kim & Lee, 2012). A recent study has also showed that MCP-1 plays an 
important role in insulin resistance that causes type 2 diabetes (Kim & Lee, 2012). As a result, 
inflammation reduction may be an important strategy in reducing the risk of obesity and 
associated type 2 diabetes (Bruun, Lihn, Pedersen, & Richelsen, 2005) . Both the altered non-
esterified fatty acid metabolism and the endocrine function hypotheses imply that visceral 
adipose tissue is causally involved in the pathophysiology of the metabolic syndrome that is 
often found in patients with visceral obesity. Therefore, visceral adipose tissue is an important 
risk factor for obesity related metabolic disorders and its reduction has become a significant aim 
in obesity management (F. M. Elisa Fabbrini, B. Selma Mohammed, Terri Pietka, Nada A. 
Abumrad, Bruce W. Patterson, Adewole Okunade, Samuel Klein, 2009). 
Type 2 diabetes is a heterogeneous disorder. It has been estimated that the risk of 
developing type 2 diabetes is higher in those who are severely obese rather than of healthy 
weight (93-fold in women and 42-fold in men) (Dixon et al., 2011). In 2013, the total prevalence 
for either type of diabetes was 25.8 million Americans, 8.3% of the population in United States, 
which approximately 90-95% of them have type 2 diabetes (Association, 2013). 
Type 2 diabetes is generally characterized as failure to appropriate respond to insulin 
(Insulin resistance). As a result, glucose access to key organs such as skeletal muscle is reduced 
and blood glucose levels remains high. This uncontrolled condition could cause blindness, nerve 
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damage, kidney disease, cardiovascular disease, and other potentially fatal complications (Bose 
et al., 2008; Mlinar, Marc, Janez, & Pfeifer, 2007). Muscle, liver, and the adipose tissue are three 
major organs in the body that are affected by insulin resistance. Under normal conditions, these 
tissues produce a response to elevated level of blood glucose, via the action of insulin. Elevated 
blood glucose can cause insulin release into the bloodstream from the β-cells in the pancreas. 
Phosphoinositide-3-kinase (PI3K) signaling cascade that activates the protein AKT is the major 
response of insulin binding to cell surface receptors in the muscle and the adipose tissue. 
Translocation of the glucose transporter type 4 (GLUT4) from the cytosol to the cell surface and 
consequently, glucose entrance to cell is caused by activation of AKT that play an important role 
in returning blood glucose to normal levels (Bose et al., 2008). Inhibition of gluconeogenic 
enzymes and suppression of hepatic glucose output in the liver is also activated by the PI3K 
cascade (Mlinar et al., 2007).  
Under insulin resistant condition, the response of muscle, adipose tissue, and liver to 
glucose uptake is reduced regardless of insulin availability in blood glucose. Therefore, the 
pancreas is producing more insulin to maintain normal blood glucose with the eventual 
development of pancreatic β-cell dysfunction. In the result, achieving glycemic control is a 
critical metabolic goal because hyperglycemia contributes to the progression of type 2 diabetes 
by adversely affecting both β-cell function and insulin sensitivity (Mlinar et al., 2007). 
Metabolic syndrome is a global emerging health concern (Vinluan, Zreikat, Levy, & 
Cheang, 2012). This syndrome has been defined by clinical symptoms such as insulin resistance, 
dyslipidemia, central obesity, hypertension, impaired glucose tolerance or diabetes mellitus 
(Miranda et al., 2005). Current research show individuals with metabolic syndrome have much 
higher risk for cardiovascular diseases. Based on the National Cholesterol Education Program’s 
11 
Adult Treatment Panel III (NCEP/ATP III) guidelines, a little more than one-third of the adults 
in the United States (34% of the US population) could be characterized as having metabolic 
syndrome (Ervin, 2009). Adults aged between 20 to 29 year have increased prevalence of 6.7% 
and ages from 60 to 69 have prevalence of 43.5% (Golden et al., 2009). According to 
NCEP/ATP III, a diagnosis of the metabolic syndrome is made when three or more of the risk 
factors shown in table 1 are present (Ervin, 2009). Metabolic syndrome increased with age but 
increased even more dramatically as BMI increased. 
Table 1 
ATP III clinical identification of the metabolic syndrome 
Risk factor Defining level 
Abdominal obesity (waist circumference)  Men  >102 cm (>40 in), Women  >88 cm (>35 in) 
Triglycerides ≥150 mg/ dL 
HDL cholesterol Men <40 mg/dL , Women  <50 mg/dL 
Blood pressure ≥135/≥85 mm Hg 
Fasting glucose  ≥100 mg/dL 
Metabolic disorders, including obesity and diabetes, can be linked to an increased 
oxidative stress (Ibarra et al., 2011). Administration of plant extracts with antioxidant ability can 
decrease this stress (Seifried, Anderson, Fisher, & Milner, 2007). These plant-based compounds 
could stimulate expression of the nuclear peroxisome proliferator-activated receptors (PPAR). 
One of these receptors, nuclear peroxisome proliferator-activated receptor gamma (PPARγ) 
directs genes that control fatty acid uptake and storage, inflammation and glucose homeostasis 
which are transcription factors that regulate energy homeostasis. This transcription factor is 
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known to promote a late-stage adipocyte marker and play important roles in the regulation of 
lipid metabolism (M. Romo Vaquero et al., 2012). 
2.2 Rosemary and Its Effects on Obesity and Related Metabolic Syndrome 
Diet rich in fruits, vegetables and herbs has been known for decades that may help to 
reduce cardiovascular and metabolic complications, but there is limited knowledge about 
components of these foods that confer health benefits (Miranda et al., 2005). Biological activities 
of plant-derived phenolic compounds have been recently considered as an excellent source to 
control these diseases, however, there are still unsolved safety and efficacy issues in humans 
(Beltrán-Debón et al., 2011). 
Recently, rosemary is one of the  appreciated sources for its health benefits including 
hepatoprotective, antibacterial, antithrombic, antiulceratic, diuretic, antidiabetic, antinociceptive, 
anti-inflammatory, antitumor and antioxidant properties (al-Sereiti, Abu-Amer, & Sen, 1999; 
Borras Linares et al., 2011; Ibarra et al., 2011; Karamadoukis, Shivashankar, Ludeman, & 
Williams, 2009). Rosemary, Rosmarinus officinalis L. (Lamiaceae), is an aromatic evergreen 
shrubby herb highly distributed in the Mediterranean region (Jalali-Heravi, Moazeni, & Sereshti, 
2011). Traditionally, rosemary has been used as a food flavoring spice and folk medicine in 
curing or managing of a wide range of diseases such as respiratory disorders, stomach problems 
and inflammatory diseases (Borras Linares et al., 2011). The water decoction of rosemary leaves 
has been traditionally used to treat diabetic patients, especially in the western part of Turkey, 
without much scientific evidence of its utility (Bakirel, Keles, Ulgen, & Yardibi, 2008). 
Rosemary is a good source for microelements and vitamins such as iron, calcium, and vitamin 
B6. 
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Application of rosemary has been verified by European Food Safety Authority as a 
natural preservative in foods and beverages. Rosemary can be found in northern African 
countries such as Morocco, and Tunisia, in southern Europe countries especially in Spain, 
France, Italy, the area of former Yugoslavia, Iran and also in America (Jalali-Heravi et al., 2011). 
Based on the studies in various cell line systems and animal models, different 
mechanisms of action have been proposed for the observed beneficial effects of RE, which could 
be attributed to its components. Though it is not clear which component is the major agent 
against obesity and metabolic syndrome (Baba et al., 2005; Bel-Rhlid et al., 2009; Hosny, 
Johnson, Ueltschy, & Rosazza, 2002). 
2.2.1 Major components in rosemary. Up to now, almost one hundred components in 
RE have been identified by using HPLC–MS or GC-MS (Borras Linares et al., 2011; Jalali-
Heravi et al., 2011). These compounds belong mainly to the classes of  phenolic diterpenes (CA, 
carnosol, rosmadial, rosmanol and its isomers epirosmanol and epiisorosmanol), flavonoids 
(genkwanin, homoplantaginin, scutellarein and cirsimaritin), triterpenes (ursolic acid, oleanolic 
acid,betulinic acid,botulin), and phenolic acids (rosmarinic acid, caffeic acid) (Bel-Rhlid et al., 
2009; Borras Linares et al., 2011; Razborsek, Voncina, Dolecek, & Voncina, 2007). The levels 
of rosemary compounds vary significantly based on the parts of the plant (leaves, stems, sepals, 
petals, seeds, roots), seasonal variation, and the extraction method (Almela, Sanchez-Munoz, 
Fernandez-Lopez, Roca, & Rabe, 2006; Razborsek, 2011). 
The principal bioactive components of the extracts are the phenolic diterpenes 
specifically CA (molecular formula C20H28O4) (Fig. 1). It is a constituent of the species Salvia 
and Rosmarinus where it is mainly to be found in the leaves of rosemary and sage. Dried leaves 
of rosemary contain between 1.5 – 2.5% CA.  Carnosol, rosmanol, epirosmanol and 
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methoxyepirosmanol are often present in less percentage than CA and also in some extent a 
result of degradation of CA with antioxidant properties (Thorsen & Hildebrandt, 2003). Some 
studies suggested that CA is therefore the only phenolic diterpene present in native state in 
rosemary and, accordingly, has the sole right to be called a natural product (Song et al., 2014). 
The molecule of CA has two physic-chemical properties; the molecule contains 
apparently polar functions, such as carboxylic acid and phenol function. On the other hand, the 
remainder of its skeleton, made up essentially of hydrocarbons, provides a relatively nonpolar 
character by contrast with all other phenolic compounds, such as the flavonoids or 
hydroxybenzoic which are present in abundance in plant. 
. 
HOOC
H
OH
HO
(4aR,10aS)-1,2,3,4,4a,9,10,10a-octahydro-5,6-dihydroxy-7-isopropyl-1,1-dimethylphenanthrene-
4a-carboxylic acid
Figure 1.  Molecular structure of carnosic acid 
CA can be oxidize to carnosol by oxidation, and carnosol can degrade further to produce 
other phenolic diterpenes (Saenz-Lopez, Fernandez-Zurbano, & Tena, 2002). The highly 
oxidized abietane diterpenes rosmanol, isorosmanol, and dimethyl isorosmanol are formed from 
CA by dehydrogenation and the participation of activated oxygen (Bonoli, Pelillo, & Lercker, 
2003) (Fig.2). Some methods for the preparation of CA by extraction have been proposed in 
literatures and patents in which the processes are long, complex. Due to economic reasons, these 
methods cannot be applied to an industrial process (Herrero, Plaza, Cifuentes, & Ibanez, 2010; 
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Okamura, Fujimoto, Kuwabara, & Yagi, 1994).  Aeschbach et al. invented a preparation process 
according to these two physic-chemical properties of CA, extraction by using first nonpolar then 
polar solvent. This process gives a residue contains between 65 to 90% CA (Robert Aeschbach, 
1993). 
Several different analytical methods have been developed in order to determine the 
content of CA in samples with comparatively simple matrices. The high-performance liquid 
chromatography (HPLC) coupled with UV and/or MS detection has been the most widely used 
methods (Sanchez-Escalante, Djenane, Torrescano, Beltran, & Roncales, 2001; Haixia Yan et al., 
2009). 
This phenolic diterpene, and its phenolic hydroxyl group is easily oxidized and degraded 
under alkaline conditions (pH > 7) and is stable at acid conditions (pH < 4). CA can easily be 
converted into carnosol by air oxidation (Mulinacci et al., 2011; Schwarz, Ternes, & 
Schmauderer, 1992). However, the results of a study by Yan et al., 2009, show carnosol was not 
found in rat plasma samples after intragastric  administration of CA in their study, indicating that 
CA could not be oxidized in vivo to generate carnosol as a metabolite (Haixia Yan et al., 2009). 
There have been only few reports for CA bioavailability and tissue distribution in rats (Doolaege, 
Raes, De Vos, Verhe, & De Smet, 2011; Haixia Yan et al., 2009), and no information for its 
metabolic profiles. Analysis of CA in rat plasma after intravenous and intragastric administration 
by Yan et al. reported a bioavailability of 65% (Haixia Yan et al., 2009). Doolaege et al. 
investigated the absorption of CA into the bloodstream after oral administration in rats. CA was 
found in the rat’s intestinal content, liver and muscle tissue of abdomen and legs. It was found 
that CA in vivo present in its free form and that the main elimination route of CA is the fecal 
route (Doolaege et al., 2011). 
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Figure 2. Formation of abietane diterpenes in rosemary plants (Munne-Bosch, Schwarz, & 
Alegre, 1999). 
2.2.2 Antiobesity and antidiabetic effects of rosemary active components 
2.2.2.1 In-vitro studies. Takahashi et al. found that CA and carnosol inhibited the 
differentiation in mouse preadipocytes (3T3-L1 cells) into adipocytes. In this study, these 
compounds induced phase 2 enzymes which are involved in metabolism of glutathione (GSH), 
activated nuclear factor E2-related factor-2 (Nrf2) and antioxidant-response element (ARE), and 
increased intracellular GSH. However, it remains unknown as yet which pathway mainly 
contributes to the inhibition by CA (Takahashi et al., 2009). 
HOOC
H
OH
HO
H
OH
HO
O
O
HOOC
H
OMe
HO
H
OH
HO
O
O
H
OH
H
OH
HO
O
O
OH
H
H
OMe
MeO
O
O
H
OH
Carnosic acid 
Carnosol 
Rosmanol Dimethylisorosmanol 
Isorosmanol 
Methoxy carnosic acid 
NAD(P)H 
Activated oxygen 
17 
 In 2012, Cui et al. demonstrated that abietane-type diterpenes from rosemary possessed 
moderate diacylglycerol acyltransferase (DGAT) inhibitory activity (Long Cui, 2012). 
Triglycerides (TG) are one of the main forms of stored energy. Excess accumulation of TG in 
certain tissues leads to serious diseases such as obesity, type 2 diabetes, and 
hypertriglyceridemia. TG synthesis has been assumed to occur primarily through (DGAT), 
which catalysis the final and only committed step in the glycerolphosphate pathway. DGAT 
activity can be promising strategy for the potential treatment of Type 2 diabetes, obesity and 
other related diseases that contain metabolic syndrome. In this study additionally, carnosol, one 
of the major components, exhibit a very effective inhibition property on de novo intracellular 
triglyceride synthesis on human hepatocyte HepG2 cells (Long Cui, 2012). CA and carnosol 
were used in an inhibitory test for pancreatic lipase activity in vitro. The inhibitory effect of CA 
was comparable to that of orlistat, and carnosol showed stronger lipase inhibitory activity than 
CA (Ninomiya et al., 2004). Tu et al. investigated the mechanisms of RE on metabolism in 
HepG2 cells. They found that RE significantly increased glucose consumption and glycolysis in 
HepG2 cells and activated the AMP-activated protein kinase (AMPK) and PPAR signaling 
pathways. They concluded that rosemary potential increased liver glycolysis and fatty acid 
oxidation by activating AMPK and PPAR pathways (Tu, Moss-Pierce, Ford, & Jiang, 2013). 
    2.2.2.2 In-vivo studies.  It has been reported that RE has significant beneficial effect on 
metabolic disorders, such as obesity, hyperlipidaemia and hyperglycaemia in many animal 
models. Harach et al. (Harach et al., 2010) demonstrated male C57BL/6J mice fed on a HFD (60 
Kcal% fat) supplemented with RE (200mg/kg BW per day, not 20mg/kg BW per day) for 50 
days were protected against weight gain induced by the HFD. Their results show RE (contains 
2.5% CA, 4% rosmarinic acid and 5.6% carnosol) was able to reduce fat mass gain and liver TG 
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content, and increase fecal fat excretion in compare to control group. The effects of RE might be 
related to the inhibition of pancreatic lipase activity (demonstrated in vitro) and caused a 
limitation of lipid absorption. In this study, the dose of CA (5mg/kg BW) was lower than that 
(20mg/kg BW) in the study of Ninomiya et al.(Ninomiya et al., 2004). They also found that 
administration of 20 or 200 mg/kg BW of RE in mice fed a HFD did not improve glucose 
tolerance, fasting plasma glucose or fasting plasma insulin level (Harach et al., 2010). 
Moreover, Ibarra et al. reported that 16-week dietary intake of RE with 20% CA 
(500mg/kg BW/day) reduced the body weight gain, as well as epididymal fat weight in HFD-fed 
(44·92% Kcal fat) male C57BL/6J mice. The plasma cholesterol level was decreased by the RE 
administration, but there was no significant difference in plasma TG and non-ester fatty acid 
(NEFA) levels.  RE treatment in this study was associated with increased fecal fat excretion. RE 
supplement was able to inhibit pancreatic lipase activity and activate PPAR-γ in vitro (Ibarra et 
al., 2011). Together, with reports of Ninomiya et al. (Ninomiya et al., 2004) and Harach et al. 
(Harach et al., 2010), the effects of limiting lipid absorption is a potential mechanism by which 
RE limits weight gain, at least partially. 
In another study, 64-day administration of RE (0.5% w/w, supplemented in standard 
chow diet) with 40% CA also reduced body weight gain and improved the plasma lipids profile 
in obese (fa/fa) and lean (fa/+) female Zucker rats through inhibiting of gastric lipase (M. Romo 
Vaquero et al., 2012). However, the decrease of levels of TG and cholesterol was only 
significant in the lean female rats. There were the same results of reducing body weight and 
increasing fecal weight as those of Harach et al. (Harach et al., 2010) and Ibarra et al. (Ibarra et 
al., 2011) studies. In this study, the levels of CA, carnosol and methyl carnosate in the 
gastrointestinal tract with RE supplement were quantified, and the highest levels of CA and 
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carnosol were found in the stomach. The methylated derivative of CA was found to be the most 
abundant in the jejunum, ileum, and liver, may be due to the action of cathecol-O-methyl 
transferases (COMTs) in the intestine and liver. The highest and most significant inhibition of 
lipase activity (70-80%) was found in the stomach of the RE treated rats, which is responsible for 
the reduction in the absorption of dietary fat.  
Few studies demonstrated positive effects of RE on improving the lipid profile in some 
animal models fed with hypercholeterolemic diet (Afonso et al., 2013; Al Sheyab, Abuharfeil, 
Salloum, Bani Hani, & Awad, 2011). Al Sheyab et al. (Al Sheyab et al., 2011) reported that the 
levels of plasma total cholesterol, low density lipoprotein (LDL), and TG were significantly 
reduced by rosemary water soluble extract administration (100 mg/kg BW) for 15 days in female 
BALB/c mice. In another study, an aqueous extract (AQ, 70 and 140 mg/kg BW) and non-
esterified phenolic fraction (NEPF, 70 and 140 mg/kg BW) were studied in rats by gavage for 4 
weeks. AQ contains 1.87% rosmarinic acid and NEPF contains 5.71% CA. However, only the 
AQ at 70 mg/kg significantly reduced the serum total cholesterol and non-HDL-c levels, maybe 
due to the amount of total phenolic compounds found in AQ was almost twice as much as in 
NEPF. Both AQ and NEPF have significant antioxidant activities in different tissues, but neither 
was able to ameliorate the alterations in the hypercholesterolemic diet-induced fatty acid 
composition in the liver (Afonso et al., 2013). 
Limited number of studies applied CA alone. CA was carried out in HFD fed mouse 
model for its anti-obese effects by Ninomiya et al. In this study, CA was given orally to male 
ddY mice fed HFD (40 Kcal % fat) for 14 days. The results show CA (20 mg/kg BW/day) 
limited body weight gain and the accumulation of epididymal fat weight. Interestingly, although 
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with three different doses of CA (5, 10, 20 mg/kg BW/day), only 10 mg/kg BW/day of CA could 
suppress the serum TG elevation. Further studies are needed to clarify this observation. 
Wang et al. analyzed the effects of CA (0.05% w/w, added in standard chow diet) in male 
ob/ob mice (obese leptin-deficient mice). After administration of CA for 5 weeks, the weight 
gain of mice was significantly inhibited and the visceral adiposity was reduced by CA 
administration. Meanwhile, the serum TG and cholesterol levels were reduced and the glucose 
tolerance was improved significantly. CA also had significantly protective effect by inhibiting 
hepatic fat accumulation and decreasing serum alanine aminotransferase (ALT) levels. CA also 
inhibited adipocyte hypertrophy of white adipose tissue (WAT) by decreasing adipocyte size (T. 
Wang et al., 2011). In good according with the results of Ninomiya et al. (2004), CA has lipid-
lowering and body weight reducing effects, and is recognized to be a novel therapeutic agent for 
obesity and obesity-related diseases. The further mechanism was studied by Wang et al. (Wang 
et al., 2012). They found the preventing effects of CA on hepatocyte lipid accumulation was 
associated with repressed PPARγ levels and activated EGFR, MAPK, AMPK and ACC, which 
regulate lipid metabolism. They concluded that EGFR/MAPK signaling pathway plays an 
important role in the effects of CA. In this study, insulin resistance itself was not actually 
examined and unexpectedly the fasting glucose in CA+ mice was higher than control group. 
In a previous study in Dr. Sang’s lab, fifty mice were categorized into 3 groups according 
to the following design: negative control group on a low-fat diet (10 kcal% fat) (n=20); control 
group on a high-fat diet (60 kcal% fat) (n=20); and a high-fat diet with 0.5% of CA enriched RE 
(40% CA) (n=10) (unpublished data). This study showed that 0.5% of RE with 40% CA in the 
diet limited weight gain and hyperglycemia in mice that were fed a HFD over 16- week. The RE 
reduced body weight gain by 54.9 %, omental fat gain by 38.9%, and retroperitoneal fat gain by 
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25.1%. It also reduced fasting blood glucose levels by 71.2% and plasma insulin levels by 92.5% 
after 16-week . Moreover the incidence of fatty livers has also been inhibited. 
Currently, substantial scientific interest is focused toward the effects of rosemary on 
obesity and obesity-related diseases. With regard to the above-mentioned, RE has been shown to 
be effective on body weight gain, fat mass gain, lowering serum lipid and glycemia in some 
animal models. However, form and mechanism of action of them have not been fully understood. 
The previous studies in this area provide a foundation for future studies that will identify the 
mechanistic bases for the metabolic effects of them. More in vivo studies are warranted to find 
weather CA is the major active component in rosemary to prevent obesity and related metabolic 
syndrome, and to further understand the underlying mechanism. 
2.3 The High-Fat Diet-Fed Mouse as an Appropriate Model for Obesity and the Metabolic 
Syndrome 
To understand metabolic syndrome and nutritional interventions related to its prevention 
or treatment, it is important to have appropriate animal models. Due to different technical skills, 
the availability of equipment, and the substances, it is unlikely metabolic experiments would be 
accomplished in the exact same way in different laboratories. Therefore the results will hardly be 
consistent from one laboratory to another. However, certain parameters can be standardized, 
regardless of where tests are conducted. This will help researchers the necessary information for 
interpreting results that might differ as a result of differences in methodology. One of the 
important parameter in metabolic studies is choosing appropriate animal model. Differences in 
these parameters can affect the results found from metabolic tests. Obesity, adipose tissue, 
glucose tolerance, Insulin resistant, and lipid levels are important elements in the metabolic 
disorders studies. One hypothesis for growing of metabolic syndrome in humans is the 
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possibility that our regulatory systems become overwhelmed by high-fat high-density foods, 
which have become increasingly available over the past 20–30 years. We chose high-fat diet-
induced obesity and diabetes mouse model because among environmental factors, the high-fat 
content of the typical Western diet is considered a major cause of obesity and related type 2 
diabetes. This mouse model was originally introduced by Surwit et al. in 1988 (Collins, Martin, 
Surwit, & Robidoux, 2004). They demonstrated that the C57BL/6J mouse would develop severe 
obesity, hyperglycemia, and hyperinsulinemia if weaned onto a high-fat diet. 
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Table 2 
In vivo studies showing the effects of Rosemary on obesity and diabetes 
Year References Treatment Dosage
/admini
stration 
route 
Animal 
model 
Time Outcomes Conclusion 
1994  Al-Hader, 
A. A., 
Hasan, Z. 
A., & Aqel, 
M. B. 
“Hypergly-
cemic and 
insulin 
release 
inhibitory 
effects of 
Rosmarinu
s 
officinalis.” 
Volatile 
oil extract 
of 
Rosemary 
i.m. 
25mg/k
g BW, 
6h 
Alloxan-
induced 
male 
diabetic 
rabbits 
6h -Serum glucose: 
Increased ~17%, 
Increased in 
normal rabbits 
after IPGTT 
-Serum 
insulin:~30%Decr
eased after 
IPGTT 30min in 
normal rabbits 
The volatile 
oil extract 
has 
significant 
hyperglyce
mic and 
insulin 
release 
inhibitory 
effects. 
 2004 Ninomiya, 
K., 
Matsuda, 
H., 
Shimoda, 
H., 
Nishida, 
N., 
Kasajima, 
N., 
Yoshino, 
T., 
Yoshikawa
, M. 
“CA, a new 
class of 
lipid 
absorption 
inhibitor 
from sage.” 
CA Oral, 
5, 10 
and 
20mg/k
g BW 
High 
fat(Olive 
oil)-fed 
male ddY 
mice 
14 d -BW Reduced by 
~7% 
-Serum TG: No 
difference for 
14days, but 
reduced at 2, 4, 
6h after 
administration 
- Serum glucose: 
level was reduced 
only at 10mg/kg 
dose for 14days 
treatment and at 
5, 10mg/kg at 2, 
4, 6h,  
-increased weight 
of Epidydimal fat 
pad. 
- Inhibited 
pancreatic lipase 
activity. 
Inhibited 
pancreatic 
lipase 
activity. 
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Cont. 
2006 Koga, K., 
Nomoto, 
K., Shibata, 
H., & 
Yoshino, 
K. 
“Effects of 
50% 
ethanol 
extract 
from 
rosemary 
on [alpha]-
glucosidase 
inhibitory 
activity and 
the 
elevation 
of plasma 
glucose 
level in 
rats, and its 
active 
compound. 
“ 
Rosemary 
50% 
ethanol 
extract 
As 
drinkin
g water 
at 
0.01% 
dose 
Maltose 
or 
sucrose 
was 
orally 
adminis
terewit
h or 
without 
rosemar
y-
distilled 
extract, 
to mice 
at a 
dose of 
20 
mg/mo
use. 
STZ-
induced 
male ddY 
diabetic 
mice 
Serum glucose: 
Decreased 
Rosemary 
may play a 
role in 
controlling 
dietary 
glucose 
uptake in 
the small 
intestinal 
tract, 
because of 
RE’s effects 
of inhibiting 
a-
Glucosidase 
activity, In 
part. 
 2007 Nusier, M. 
K., 
Bataineh, 
H. N., & 
Daradkah, 
H. M. 
”Adverse 
effects of 
rosemary 
on 
reproductiv
e function 
in adult 
male rats.” 
Rosemary 
70% 
ethanol 
extract 
As 
drinkin
g water 
at 250 
and 500 
mg/kg 
BW 
Male 
Sprague-
Dawley 
rats 
63da
ys 
-Body weight: No 
difference 
-Serum TG: No 
difference 
-Serum 
cholesterol: No 
difference 
- Serum glucose: 
No difference 
-No difference in 
ALT and AST 
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 2008 Bakirel, T., 
Keles, O. 
U., Ulgen, 
S. G., & 
Yardibi, H. 
“In vivo 
assessment 
of 
antidiabetic 
and 
antioxidant 
activities of 
rosemary 
in alloxan-
diabetic 
rabbits.” 
Rosemary 
95% 
ethanol 
extract 
Oral, 
50, 
100, 
200 
mg/kg 
BW, 
Normal
 , acute 
at 1, 2, 
6h, and 
at 
Subacut
e blood 
samples 
were 
collecte
d at 1st, 
3rd, 
5th, and 
8th 
days 
after 
each 
treatme
nt. 
Alloxan-
induced 
diabetic 
adult 
rabbits of 
either sex 
7day
s 
-Body weight: 
increased 
- Serum glucose: 
 Acute: decreased 
only in 200mg/kg 
at 2 and 6h. 
Subcute: 
decreased in 8th 
day with 
100mg/kg and 
decreased in 
200mg/kg from 
3rd day. 
-Serum insulin: 
Acute: increased 
only in 200mg/kg 
at 2 and 6 h. 
Subcute: 
increased in 8th 
day with 
100mg/kg and 
increased in 
200mg/kg from 
3rd day 
- Normal: 
decreased in 100 
mg/kg after 2h of 
oral 
administration 
and recovered at 
6h. Decreased in 
200 mg/kg after 2 
and 6h. No 
change in insulin. 
And decreased in 
100 mg/kg at 6h 
and in200mg/kg 
at 2, 6h after 
OGTT. No 
insulin change. 
Hypoglycae
mic action 
was 
observed to 
be dose 
dependent. 
The RE 
exerts 
remarkable 
hypoglycae
mic and 
antihypergly
caemic 
activity due 
to its 
possible 
multiple 
effects 
involving in 
pancreatic 
and extra-
pancreatic 
and 
antioxidant 
mechanism. 
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Table 2 
Cont. 
2010 Harach, T., 
Aprikian, 
O., 
Monnard, 
I., Moulin, 
J., 
Membrez, 
M. 
“Rosemary 
leaf extract 
limits 
weight gain 
and liver 
steatosis in 
mice fed a 
high-fat 
diet.” 
RE(contai
ns 4% 
rosmarinic 
acid, 2.5% 
CA, and 
5.6% 
carnosol) 
Oral, 
20 
mg/kg 
BW 
and 
200mg/
kg 
BW(0.2
5% and 
0.025% 
W/W 
diet) 
HFD fed 
male 
C57BL/6
J mice 
50 
days 
-Body weight: 
Reduced by 
~11% with 
200mg/kg dose 
-Liver TG: 
Reduced  with 
200mg/kg 
-Serum TG: No 
difference 
-Serum 
cholesterol: No 
difference 
-Serum glucose: 
No difference 
-Serum insulin: 
No difference 
- RE induced a 
higher fecal fat 
excretion 
The results 
suggest that 
RE did not 
regulate 
glucose 
homeostasis 
in diet-
induced 
obesity mice 
but RE 
induced a 
higher 
faecal fat 
excretion 
inhibited 
pancreatic 
lipase 
activity in 
vitro. 
2011 Wang, T., 
Takikawa, 
Y., Satoh, 
T., 
Yoshioka, 
Y., Kosaka, 
K., 
Tatemichi, 
Y., & 
Suzuki, K. 
“CA 
prevents 
obesity and 
hepatic 
steatosis in 
ob/ob 
mice.” 
CA Oral, 
0.05% 
(w/w) 
Male 
obese 
leptin-
deficient 
(ob/ob) 
mice 
 5 
week
s 
-Body weight: 
Decreased  
- Serum TG: 
Reduced by ~ 
60% 
- Serum 
cholesterol: 
Reduced by 
~24%  
- Liver TG: N  
-Serum glucose: 
Reduced by 
~18%  
-Serum insulin: 
Decreased by 
47% 
- No difference in 
food intake. 
-Plasma FFA 
decreased. 
CA 
inhibited 
adipocyte 
hypertrophy 
of WAT by 
a decrease 
of adipocyte 
size. 
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Table 2 
Cont. 
2011 Ibarra, A., 
Cases, J., 
Roller, M., 
Chiralt-
Boix, A., 
Coussaert, 
A., & 
Ripoll, C. 
“CA-rich 
rosemary 
leaf extract 
limits 
weight gain 
and 
improves 
cholesterol 
levels and 
glycaemia 
in mice on 
a high-fat 
diet.” 
RE (20% 
CA) 
Oral, 
500mg 
/kg BW 
HFD fed 
male 
C57BL/6
J mice 
16-
week 
-Body weight: 
Decreased 
- Serum TG: No 
difference 
- Serum 
cholesterol: 
Reduced  
-Serum glucose: 
Decreased  
- Serum insulin: 
No difference 
- RE increased 
fecal total lipid 
excretion and 
fecal energy 
excretion, and 
decreased 
pancreatic lipase 
activity. 
Anti-
hyperglyce
mic activity 
in a HFD 
mouse 
model. 
2012 Romo 
Vaquero, 
M., Yanez-
Gascon 
“Inhibition 
of gastric 
lipase as a 
mechanism 
for body 
weight and 
plasma 
lipids 
reduction 
in Zucker 
rats fed a 
RE rich in 
CA.” 
RE (40% 
CA) 
Oral, 
0.5% 
(w/w) 
(RE 
350-
700 
mg/kg; 
CA, 
140 -
280 
mg/kg ) 
Female 
Zucker 
lean(fa/+
) and 
obese 
(fa/fa) 
rats 
 64 
days 
-Body weight: 
Reduced by 15% 
-Serum TG : 
Decreased in lean 
rats, but no 
difference in 
obese rats 
-Serum 
cholesterol: 
Decreased in lean 
rats, but no 
difference in 
obese rats 
-Liver TG: No 
difference 
-Serum glucose: 
No difference 
-Serum insulin: 
reduced in leans.  
-RE 
significantly 
inhibited 
gastric 
lipase 
activity in 
the 
stomach , 
which may 
cause a 
moderate 
reduction of 
fat 
absorption. 
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Table 2 
Cont. 
2012 Al Sheyab, 
F. M., 
Abuharfeil, 
N., 
Salloum, L. 
“The effect 
of 
rosemary 
plant 
extracts on 
the 
immune 
response 
and lipid 
profile in 
mice.” 
RE (water 
soluble 
extract) 
Oral, 
100mg/
kg BW 
d 
High 
cholester
ol diet 
fed 
female 
BALB/c 
mice 
15da
ys 
- Serum TG: 
Reduced 
-Serum 
cholesterol: 
Reduced 
- LDL decreased 
and HDL 
significantly 
increased by RE 
supplement. 
-
Hypolipide
mic activity 
of RE 
2012 Aljamal, A. 
“Effects of 
rosemary 
on lipid 
profile in 
diabetic 
rats.” 
RE hot 
water 
extract 
Oral, 
550 
mg/mo
use/day 
STZ-
induced 
male 
albino 
rats 
 4 
week
s 
- Serum TG : 
Decreased by 
24% 
- Serum 
cholesterol: 
Decreased by 
22% . 
- Serum glucose: 
Decreased 
by20%LDL 
decreased by 27% 
and HDL 
increased by18%. 
-RE had a 
Hypoglyce
mic effect 
and 
improved 
the lipid 
profile. 
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Table 2 
Cont. 
2013 Milessa S 
Afonso, A. 
M. d. O. S., 
Eliane BT 
Carvalho, 
Diogo P 
Rivelli, 
Sílvia BM 
Barros,, & 
Marcelo M 
Rogero, A. 
M. L., 
Rosângela 
P Torres 
and Jorge 
Mancini-
Filho. 
“Phenolic 
compounds 
from 
Rosemary 
attenuate 
oxidative 
stress and 
reduce 
blood 
cholesterol 
concentrati
ons in diet-
induced 
hyperchole
sterolemic 
rats.” 
Rosemary 
aqueous 
extract 
(AQ, 
contain 
1.87% 
Rosmarini
c acid)and 
non-
esterified 
phenolic 
fraction 
(NEPF, 
contain 
5.71% 
CA) 
AQ 70 
and 140 
mg/kg 
BW, 
NEPF 7 
and 14 
mg/kg 
BW 
Hypercho
lesterole
mic diet 
fed male 
Wistar 
rats 
4 
week
s 
-Body weight: No 
difference 
-Serum TG: No 
difference 
-Serum 
cholesterol: Only 
decreased in 
70mg AQ/kg 
dose. 
-No difference in 
food intake.    
-70mg AQ/kg 
dose decreased 
non-HDL-
cholesterol. 
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CHAPTER 3 
Methodology 
3.1 Materials 
Rosemary Extract: The RE with 45% CA used in this study was purchased from China. 
Mice: Seventy-five male C57BL/6J mice, aged 5 weeks were purchased from Jackson 
Laboratories (Bar Harbor, ME, USA). 
-  Low-fat diet (10 Kcal%, 4.3 % fat w/w), high-fat diet (60 Kcal%, 35% fat w/w), high 
fat with 0.50% w/w RE with 45% CA, high fat with 0.28% w/w RE with 80% CA, high fat with 
0.14% w/w RE with 80% CA were made by Research Diets, Inc. (New Brunswick, NJ) (Table 
3). 
3.2 Experimental Methods 
3.2.1 Experiment 1- Preparation of RE with 80% CA and CA (95%) standard. RE 
with 80% CA and CA standard were freshly prepared from the RE (45% CA) in our lab. 
3.2.1.1 Extraction and isolation. CA was prepared according to the U.S. patent 
5,256,700 (Robert Aeschbach, 1993) in our lab with modification (Fig. 3). In brief, 50 g RE 
(45% CA) was subjected to column chromatography over silica gel (230-400 mesh, Sorbent 
Technologies Inc., Atlanta, GA) and was eluted with a gradient of hexane-acetone (50:2, 50:3, 
50:4, 50:5, 0:100; 1000 mL each) to give 5 fractions (Fr. A-E). 
Purification of fraction B (23.3g) by reverse phase C18 silica gel medium pressure column 
chromatography (35 mm × 400 mm, 60 Å, Sigma) eluted with 75% methanol /water containing 
0.05% formic acid, gave four sub fractions (Fr. B1-B4). Fraction B2 (6.85 g) was identified as the 
CA enriched fraction (80% CA) by HPLC-MS. In order to get enough samples for the mouse 
study, this procedure was repeated five times. For further purification, 5.0 g of fraction B2 was 
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loaded to Sephadex LH-20 column chromatography using ethanol as eluent, and only 0.5 g pure 
CA (98%) was obtained. 
Rosemary extract (45% CA); 50 g 
Hexane/ Acetone 
Normal phase silica gel column 
50:2 50:3      50: 4 50:5 100% Acetone 
Figure 3. Separation scheme to prepare RE with 80% CA and purified CA (98%). 
3.2.1.2 Analysis of CA by NMR. Nuclear magnetic resonance (NMR) was used for 
confirming the CA structure. 
1
 H and 
13
 C NMR spectra (analyzed in CDCL3) were recorded on a
Bruker AVANCE 700 MHz spectrometer (Brucker, Silberstreifen, Rheinstetten, Germany). 
Fraction A Fraction B Fraction C Fraction D Fraction E 
Methanol/Water (75%) 
Reverse phase C18 silica gel column 
Fraction B1 Fraction B2; (80% CA);
 
5 g     Fraction B3
 
Fraction B4
Ethanol 
Sephadex LH- 20 column 
Fraction BS1
 Fraction BS2; (98% CA); 0.5 g
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3.2.1.3 Analysis of the major components in RE by HPLC/ECD and LC/ESI-MS. 
3.2.1.3.1 HPLC/ECD analysis. A high-performance liquid chromatography/ESA 
electrochemical detector (HPLC-ECD) (ESA, Chelmsford, MA) consisting of an ESA model 584 
HPLC pump, an ESA model 542 autosampler, an ESA organizer, and an ESA CoulArray 
detector coupled with two ESA model 6210 four sensor cells, was used in the current study. A 
Gemini C18 column (150 × 4.6 mm, 5 μm; Phenomenex, Torrance, CA) was used for 
chromatographic analysis at a flow rate of 1.0 mL/min. The mobile phases consisted of solvent A 
(30 mM sodium phosphate buffer containing 1.75% acetonitrile and 0.125% tetrahydrofuran, pH 
3.35) and solvent B (15 mM sodium phosphate buffer containing 58.5% acetonitrile and 12.5% 
tetrahydrofuran, pH 3.45). The gradient elution had the following profile: 5% B from 0 to 3 min; 
5 to 55% from 3 to 10 min; 55 to 100% from 10 to 40 min; 100% B from 40 to 45 min; and 5% 
B from 45.1 to 50min. The cells were then cleaned at a potential of 1000 mV for 1 min. The 
injection volume of the samples was 10 μL. The eluent was monitored by the Coulochem 
electrode array system (CEAS) with potential setting at -50, 100, 200, 300, 400, 500, and 600 
mV. 
3.2.1.3.2 LC/ESI-MS analysis. LC/MS was carried out with a Thermo-Finnigan Spectra 
System, which consists of an Accela high-speed MS pump, an Accela refrigerated auto sampler, 
and an LTQ Velos ion trap mass detector (Thermo Electron, San Jose, CA) incorporated with an 
electrospray ionization (ESI) interface. A Gemini C18 column (150 × 4.6 mm, 5 μm; 
Phenomenex, Torrance, CA) was used for separation at a flow rate of 200 µL/ min. The column 
was eluted with 100% solvent A (5% aqueous methanol with 0.2% acetic acid) for 3 min, 
followed by linear increases in B (95% aqueous methanol with 0.1% acetic acid) to 60 % from 3 
to 8 min; then to 75 % from 8 to 30 min, to 82 % from 30 to 48 min; and then with 100% from 
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48 to 55 min. The column was then re-equilibrated with 100 % A for 5 min. The injection 
volume was 10 µL for each sample. Nitrogen gas was used as the sheath gas and auxiliary gas. 
The collision-induced dissociation (CID) was conducted with an isolation width of 2 Da and 
normalized collision energy of 35 for MS
2
 and MS
3
. The mass range was measured from 50 to
1000 m/z. Data acquisition was performed with Xcalibur version 2.0 (Thermo Electron, San Jose, 
CA, USA). 
3.2.2 Experiment 2 –Animal study and biological analysis. All animal experiments 
were conducted according to protocol (ID: 12-012) approved by the Institutional Animal Care 
and Use Committee at the North Carolina Research Campus (NCRC) in Kannapolis. 
3.2.2.1 Animal and diets. All mice were housed on a 12-hour light/ dark cycle in a 
temperature-controlled environment during 1-week acclimatization, with ad libitum access to 
water and diet. After acclimatization, mice were randomized into 5 groups (n=15). Each group 
was fed the following experimental diet for 16-week : low-fat diet (10 Kcal%, 4.3 % fat w/w, 
LFD), high-fat diet (60 Kcal%, 35% fat w/w, HFD), high fat with 0.50% RE (enriched with 45% 
CA, RE#1), high fat with 0.28% w/w RE (enriched with 80% CA, RE#2H), high fat with 0.14% 
w/w RE (enriched with 80% CA, RE#2L) (Table 4). 
  Body weight and drink intake were measured weekly. Food intake was recorded every 
day. Signs of abnormality and possible toxicity were monitored. At the end of the study, liver, 
omental fat, and retroperitoneal fat were harvested, rinsed, and weighed. In addition, for 
measuring fecal lipid levels, from each group 5 mice were placed at a metabolic cage and 24-
hour fecal samples were collected at week 16. All samples were stored at -80 ºC. Fasting blood 
glucose was measured at 0, 10, and 16-week of treatment. Food was removed 6 h prior to blood 
glucose measurements. Blood was collected from the tail vein, and glucose levels were measured 
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with One Touch Ultra 2 glucose monitor (Life scan, Inc. Milpitas, CA, USA). Mice were food-
deprived for 8 hours and sacrificed by isophorone inhalation after 16-week of treatment. Whole 
blood was obtained by cardiac puncture. Blood samples were centrifuged at 5,000 rpm for 15 
min.  
3.2.2.2 Biochemical analysis of plasma samples. Biochemical levels were measured 
using commercial kits. Plasma alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) activities were colorimetrically measured using Infinity ALT and AST Reagent provided 
by Thermo Scientific (Waltham, MA). Plasma triglyceride and cholesterol concentrations were 
measured by Infinity Triglyceride and Infinity Cholesterol Reagent (Thermo Scientific), 
respectively. Plasma free fatty acid was determined with a Free Fatty Acid Quantification Kit 
(BioVision, Milpitase, CA). Insulin levels were determined using Ultrasensitive Insulin ELISA 
kit (ALPCO, Salem, NH). Glucose levels in tail vein blood samples were measured using an 
OneTouch Ultra2 Blood Glucose Meter (LifeScan, Milpitase, CA). 
3.2.2.3 Determination of lipid concentrations in liver. Quantitative assay of lipids was 
conducted by measuring triglyceride, cholesterol and FFA concentrations in the liver. In brief: 
hepatic lipids are extracted by homogenizing liver tissue in chloroform using 1% Triton X-100. 
The organic extracts were air dried, vacuumed, and dissolved in Trition X-100. Triglyceride, 
cholesterol, and FFA concentrations in extracts were determined using commercial kits (see 
Blood Biochemical Markers). 
3.2.2.4 Body composition. A nuclear echo magnetic resonance imaging whole-body 
composition analyzer (Echo MRI System, Kannapolis, NC, USA) was used to assess body fat 
and lean mass in conscious mice. One cage was chosen from each group in week 15. 
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3.2.2.5 Fecal lipid measurements. The feces harvested during a 24-hour period, were 
collected at week 16; frozen at -80°C; and pulverized. Total lipids were extracted from 100 mg 
of dried feces using the following method (Folch, Lees, & Stanley, 1957): The feces were 
cleaned and dried for 24 hours by freeze dryer, incubated with 2 mL of chloroform-methanol 
(2:1) for 30 min at 60°C with constant agitation, and then centrifuged. Water (1 mL) was added 
to the supernatant, and following vortexing, phase separation was induced by low-speed 
centrifugation (2,000 rpm for 10 min). The lower chloroform phase was then removed and 
transferred to a new tube, and the sample was evaporated to dryness by nitrogen evaporator and 
weighed. 
3.2.2.6 Statistical analysis. The data from the in vivo studies were expressed as mean ± 
standard deviation (x ± SD). One-way analysis of variance (ANOVA one-way, Newman-Keuls 
multiple comparison test) and student t-test were performed to compare groups using Sigma Plot 
11.0 (2008) (Systat Software, Inc.). Statistical significance was considered at p<0.05.
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Table 3 
Composition of the experimental diets. 
  
Macronutrient 
          LFD          HFD HFD + RE#1 
(0.5%) 
HFD + RE#2H 
(0.28%) 
HFD + RE#2L 
(0.14%) 
   g %       Kcal %   g %           Kcal
%  
   g %            kcal 
% 
   g %       kcal 
% 
  g %           kcal
% 
Protein 19.2 20 26.2 20 26.1 20 26.2 20 26.2 20 
Carbohydrate 67.3 70 26.3 20 26.2 20 26.3 20 26.3 20 
Fat 4.3 10 34.9 60 34.7 60 34.8 60 34.8 60 
Total  100  100  100  100  100 
Kcal/g 3.85  5.24  5.22  5.23  5.24  
           
Ingredient      g           kcal       g           kcal       g            kcal       g           kcal       g            kcal 
Casein/80 mesh 200 800 200 800 200 800 200 800 200 800 
L-Cystine 3 12 3 12 3 12 3 12 3 12 
           
Corn starch 506.2 2024.8 0 0 0 0 0 0 0 0 
Maltodextrin 10 125 500 125 500 125 500 125 500 125 500 
Sucrose 68.8 275.2 68.8 275.2 68.8 275.2 68.8 275.2 68.8 275.2 
           
Cellolose,BW2
00 
50 0 50 0 50 0 50 0 50 0 
           
Soybean oil 25 225 25 225 25 225 25 225 25 225 
Lard 20 180 245 2205 245 2205 245 2205 245 2205 
           
Mineral 
mix,S10026 
10 0 10 0 10 0 10 0 10 0 
D Calcium 
Phosphate 
13 0 13 0 13 0 13 0 13 0 
Calcium 
carbonate 
5.5 0 5.5 0 5.5 0 5.5 0 5.5 0 
Potassium 
citrate, 1 H2o 
16.5 0 16.5 0 16.5 0 16.5 0 16.5 0 
           
Vitamin mix, 
V10001 
10 40 10 40 10 40 10 40 10 40 
Cholin Biartrate 2 0 2 0 2 0 2 0 2 0 
           
RE#1 0 0 0 0 3.9 0 0 0 0 0 
RE#2 0 0 0 0 0 0 2.18 0 1.09 0 
           
Dye 0.05  0.05  0.05  0.05  0.05  
           
Total 1055.05 4057 773.85 4057 777.75 4057 776.03 4057 774.94 4057 
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CHAPTER 4 
Results 
4.1 Experiment 1- Characterization of the Major Components in REs. 
4.1.1 Structure elucidation of purified CA from commercial RE by NMR. The 
structure of CA was identified using NMR techniques and confirmed by comparison of its NMR 
data with those already published (Masuda, Inaba, & Takeda, 2001; H. Yan et al., 2009). 
Multiplicities are indicated by s (singlet), d (doublet), and brd (broad doublet) (Table 4, Fig. 4 A, 
B). 
4.1.2 HPLC/ECD and LC/MS analysis. 
4.1.2.1 Determination of the purity of CA standard by HPLC/ECD. CA standard was 
purified by the combination of different column chromatography techniques in our lab. The 
purity of CA standard was obtained based on the analysis of peak areas generated automatically 
from CoulArray Data Station 3.00 (ESA Biosciences, MA). In a same manner, the content of CA 
in RE was also quantified. 
4.1.2.2 LC/MS analysis. LC/MS analysis of the prepared REs revealed a total of three 
major diterpene phenolic compounds present in the extracts. The compounds were characterized 
by their retention times, UV-Vis and mass spectrum, and identified by comparison with 
published data (H. Yan et al., 2009) or commercial standards. Figure 5 A shows, the 
chromatographic profile of the commercial RE with 45% CA. CA was shown in the middle and 
the highest peak. After extraction of the commercial product, the figure 5 B shows the 
chromatographic profile of the RE with 80% CA. LC/ESI-MS results demonstrated that for CA 
related compounds, the neutral loss of a CO2 molecule (44 Da) was regarded to be a 
characteristic fragmentation pathway (María Romo Vaquero et al., 2013; Song et al., 2014). Take 
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CA (Peak Ⅰ, at retention time of 36.5 min) for example, the MS spectrum of CA exhibited and 
deprotonated ion at m/z 331 [M-H]
-
 (data not shown), corresponding to a molecular weight of
332 amu, MS
2
 spectrum (Fig. 5D) of the precursor ion at m/z 331 [M-H]
-
 afforded a predominant
product ion at m/z 287, generating by the neutral loss of a CO2 (44 Da) from the carboxyl 
moiety. Likewise, the other two major peaks (Peak Ⅱ and Ⅲ, at retention times of 32.7 and 40.1 
min, respectively) were tentatively identified as carnosol and 12-O-methyoxy CA by comparing 
their MS/MS data with the reference data from literature(Song et al., 2014). The stability of 
extracts was tested by monitoring the content of CA using HPLC-DAD-MS/MS. The levels of 
CA in the experimental diets remained stable throughout the study period. 
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Figure 4. 
1
H and 
13
 C NMR spectra of CA
(A) 
(B) 
OH
HO
HOOC
Two doublet 
methyls. 
Two singlet 
methyls. 
OH
HO
HOOC
Four methyls Six aromatic signals 
-COOH 
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Table 4 
NMR spectra data of CA 
 CA  
position δH multi (J) δC 
1 1.63 m 41.9 
2 : 1.90 m 
: 2.39 m 
18.9 
3 2.86 m 34.4 
4  34.4 
5 1.78 m 53.9 
6 : 1.52 m 
: 1.60 brd (11.6) 
20.3 
7 : 1.34 m 
: 3.32 brd (13.9) 
31.5 
8  129.0 
9  122.1 
10  48.7 
11  142.1 
12  141.4 
13  133.7 
14 6.57 s 119.4 
15 3.21 m 27.2 
16 1.23 d (7.0) 21.7 
17 1.23 d (7.0) 22.2 
18 1.04 s 32.6 
19 0.93 s 22.5 
20  182.4 
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Figure 5. TIC chromatograms of commercial RE (A), CA enriched RE (B), and MS/MS 
(negative) spectra of peak Ⅰ(C), Ⅱ(D)and Ⅲ(E). 
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4.2 Experiment 2- Animal Study and Biological Analysis 
4.2.1 Effects of REs on body and organ weight and food intake in mice fed a high-fat 
diet. Body weight between the HFD and LFD groups began to differ significantly after the first 
week of treatment (p<0.01). Likewise, body weight between the HFD and the three RE treated 
groups started to differ significantly (p<0.05) after the first week of experiment (Fig. 6). At the 
end of the study, LFD group had 58% less weight gain than HFD. Weight gain for all treatment 
groups (RE#1, RE#2H and RE#2L) were less than that of HFD at 48, 52 and 32% ( p<0.05) at 
the end of the study, respectively (Fig. 7). 
After 16-week treatment, LFD group had 72% mesenteric fat, 70% perirenal fat, 56% 
total fat and 57 % liver weight less than HFD group. The three treated groups (RE#1, RE#2H, 
and RE#2L) had 67, 69 and 54 % (p<0.05) less than HFD group in mesenteric fat; 41, 50 and 26 
% less than HFD group in perirenal fat; 23.5, 32 and 5 % (p<0.05) less than HFD group in total 
fat , 54, 57and 53 % less than HFD group  in liver weight, respectively. No significant changes 
were observed between groups in epididymal fat (Table 5). An obvious difference between the 
mouse abdominal cavities has been observed at the necropsy room. 
The above results were further supported by the MRI results. The figures generated from 
the MRI demonstrate that the weight gain reduction by RE#1 and RE#2H groups are due to 
decrease the fat mass (Fig. 8). 
The HFD was very soft and easily crushed and dumped into the cage. Therefore, it is not 
possible for us to accurately measure the food intake even we tried to measure it every day. Most 
of the literature studies reported that between RE treated group and HFD group there was no 
significant difference in food intake(Harach et al., 2010; T. Wang et al., 2011). However, it is 
unclear to us how they could measure the food intake in an accurate way. 
43 
. 
Figure 6. Effects of low fat diet (LFD), high fat diet (HFD), 0.5% RE with 45% CA (RE#1), 
0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) on body weight of 
mice during 16-week experiment. Values are means, with standard deviations represented by 
vertical bars. Dis similar letters are significantly different at the P<0.05 level, n=15. 
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Figure 7. Effects of low fat diet (LFD), high fat diet (HFD), 0.5% RE with 45%  CA (RE#1), 
0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) on weight gain after 
16-week. Values are means, with standard deviations represented by vertical bars. Values with 
different letter are significantly different at the P<0.05 level, n=15. 
Table 5 
Effects of low fat diet (LFD), high fat diet (HFD), 0.5% RE with 45%  CA (RE#1), 0.28% RE 
with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L), on weight parameters (mesenteric 
fat, perinenal fat, epidididymal , total fat and liver after 16-week. 
Parameter LFD HFD RE#1 RE#2H Re#2L 
Mesenteric fat 0.48 ± 0.15 1.71 ± 0.24 0.55 ± 0.21 0.54  ± 0.13 0.78  ± 0.22 
Perirenal fat 0.48  ± 0.21 1.58 ± 0.33 0.93 ± 0.28 0.79 ± 0.31 1.16 ± 0.24 
Epidididymal fat 1.16 ± 1.16 1.54 ± 1.54 2.21 ± 2.21 1.96 ± 1.96 2.63 ± 2.63 
Total fat 2.13 ±0.82 4.84 ± 0.46 3.7 ± 1.14 3.3 ± 1.12 4.59  ± 1.12 
Liver weight 1.18 ± 0.26 2.78 ± 0.6 1.27  ± 0.15 1.19 ± 0.14 1.3  ± 0.27 
 The results are expressed as the mean± SD (n=15)
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Figure 8. Body composition results of Eco-MRI. The Results of the total weight (A), total fat 
(B), lean mass% of the body weight (C) and fat mass% of the body weight (D) after 16-week of 
treatment by LFD, HFD, RE#1, RE#2H and RE#2L. Values are mean ± SD. Values with 
different letter are significantly different at the P<0.05, n=5. 
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4.2.2 Effects of RE on serum biochemical parameters. After 16-week of treatment, 
total plasma cholesterol level rose significantly in the HFD group compared with LFD animals. 
Plasma cholesterol in LFD compare to HFD is 49% less; in treatment groups, (RE#1, RE#2H 
and RE#2L) are 19, 34 and 18% less than HFD, respectively (Fig. 9). However, Plasma 
triglyceride and plasma free fatty acids in the HFD group compared with LFD animals are not 
significantly different (Fig. 10, Fig. 11). 
Figure 9. Effects of low fat diet (LFD), high fat diet (HFD), 0.5% RE with 45% CA (RE#1), 
0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) on plasma cholesterol 
after 16-week. Values are means, with standard deviations represented by vertical bars, P<0.05, 
n= 6. 
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Figure 10. Effects of low fat diet (LFD), high fat diet (HFD), 0.5% RE with 45% CA (RE#1), 
0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) on plasma triglyceride 
after 16-week. Values are means, with standard deviations represented by vertical bars, n= 6. 
Figure 11. Effects of low fat diet (LFD), high fat diet (HFD), 0.5% RE with 45% CA (RE#1), 
0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) on plasma free fatty 
acid after 16-week. Values are means, with standard deviations represented by vertical bars, n= 
6. 
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Total glucose levels in LFD group are 21% less than those in HFD group. Mice in 
treatment groups (RE#1, RE#2H, and RE#2L) experienced 15, 22 and 17 % plasma glucose 
levels (p<0.001) less than those in HFD group (Fig. 12 A). Fasting blood glucose levels in all the 
groups were recorded at week 0, 10, and 16 as reported in Figure 12A. 
Animals in the LFD group had normal fasting blood glucose level after the 16-week 
treatment (160.73±22.72 mg/dl at Week 0; 126.10±20.54 mg/dl at Week 10; 171.6±21.76 mg/dl 
at Week 16). In contrast, HFD animals increased fasting blood glucose levels progressively from 
the beginning of the study (146.73±21.54 mg/dl) until Week 16 (221.66±28.40 mg/dl). 
In the RE-treated groups, fasting blood glucose rose 19.36%  in RE#1, 26.31% in 
RE#2H, and 17.53% in RE#2L (178.73±22.22 md/dl , 163.33±20.70 md/dl, 182.8±24.67 md/dl , 
p<0.001 ) less than those in HFD mice at the end of the study. There is no significant difference 
between blood glucose levels between the two of the treatment groups (RE#1 and RE#2H) and 
the LFD group after 16 week. 
Figure 12B shows the levels of fasting plasma insulin at the end of the study, week 16. 
Reduced fasting plasma insulin levels was significantly different between LFD and HFD, and 
also between treatment groups (RE#1, RE#2H, Re#2L) and HFD group (p<0.001). Insulin level 
in LFD compare to HFD is 69% less; in treatment groups (RE#1, RE#2H and RE#2L) are 66, 59 
and 50% less than HFD, respectively. There is no significant difference of the fasting plasma 
insulin levels between two of the treatment groups (RE#1 and RE#2H) and LFD group after 16 
week. 
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Figure 12. (A) Fasting blood glucose levels in low fat diet (LFD), high fat diet (HFD), 0.5% RE 
with 45% CA (RE#1), 0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) 
treated mice at week 0, 10, and 16. (B) Fasting plasma insulin levels in LFD, HFD, RE#1, 
RE#2H and RE#2L treated mice after 16-week study. Values are mean ± SD, * = P<0.05, n= 6. 
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4.2.3 Changes in liver weight, incidence of fatty liver, and plasma ALT and AST 
levels. After 16-week of treatment, the average liver weight reached 1.18±0.26 g in the LFD 
group, 2.78 ±0.60 g in the HFD group, and less liver weight 54.1, 57 .21 and 53.11% in RE#, 
RE#2H, Re#2L compare to HFD group(P<0.05) ( Fig. 13). 
Figure 13. Liver weight in low fat diet (LFD), high fat diet (HFD), 0.5% RE with 45% CA 
(RE#1), 0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) groups after 
the 16-week study. Values are mean ± SD, * = P<0.05, n= 6. 
Liver triglyceride level in LFD compare to HFD is 85% less; and in treatment groups 
(RE#1, RE#2H and RE#2L) are 92, 93 and 78% less than that in HFD, respectively (Fig. 14). 
Hepatic cholesterol increased significantly in LFD and all treatment groups compare to HFD 
group (P<0.05) (Fig. 15). .Free fatty acid in liver level in LFD compare to HFD is 77% less, in 
treatment groups, (RE#1, RE#2H and RE#2L) are 83, 82 and 73% less than HFD, respectively 
(Fig. 16). 
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Figure 14. Hepatic triglyceride levels in low fat diet (LFD), high fat diet (HFD), 0.5% RE with 
45% CA (RE#1), 0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) 
treated mice after 16-week study. Values are mean ± SD, * = P<0.05, n= 6. 
Figure 15. Hepatic cholesterol levels in low fat diet (LFD), high fat diet (HFD), 0.5% RE with 
45% CA (RE#1), 0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) 
treated mice after 16-week study. Values are mean ± SD, n= 6. 
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Figure 16. Hepatic free fatty acid levels in low fat diet (LFD), high fat diet (HFD), 0.5% RE with 
45% CA (RE#1), 0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) 
treated mice after 16-week study. Values are mean ± SD,* = P<0.05, n= 6. 
In addition, plasma ALT levels in LFD, RE#1, RE#2H, RE#2L treated mice were 
significantly different compare to the HFD group (P<0.001). In LFD group, plasma ALT level 
compare to HFD is 74% less and in treatment groups, (RE#1, RE#2H and RE#2L) are 74, 71 and 
76% less than HFD, respectively. There are no significance differences between LFD and the 
treated groups (Fig. 17A). 
Plasma AST levels in LFD, RE#1, RE#2H, RE#2L animals were significantly different 
compare to the HFD group (P<0.05). AST level in LFD compare to HFD is 40% less, in 
treatment group, (RE#1, RE#2H and RE#2L) are 47, 49 and 39% less than HFD, respectively. 
There are no significance differences between LFD and the treated groups (Fig. 17B). 
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Figure 17. Plasma ALT (A) and AST (B) levels in low fat diet (LFD), high fat diet (HFD), 0.5% 
RE with 45% CA (RE#1), 0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA 
(RE#2L) groups. Values are mean ± SD, * = P<0.001, n= 6. 
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4.2.4 Effect of RE on fecal fat excretion. Animals in HFD group had higher fecal fat 
excretion values (2.58±0.41 mg/100 mg) compared with those in LFD group (1.39 ± 0.17 
mg/100 mg, P<0.05). Lipid excretion among HFD and animals with three RE treatment groups 
were significantly different, RE#1 (5.06 ± 0.82 mg/100 mg, P<0.05), RE#2H (4.09 ± 0.27 
mg/100 mg, P<0.05), RE#2 L (3.94 ± 0.49 mg/100 mg, P<0.05) in the last week of the 
experiment (Fig. 18). 
Figure 18. Effects of RE on lipid excretion in low fat diet (LFD), high fat diet (HFD), 0.5% RE 
with 45% CA (RE#1), 0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) 
groups. Results are presented as means ± S.D, * = p<0.05, n=3. 
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CHAPTER 5 
Discussion and Future Research 
In this doctoral thesis, we developed column chromatography techniques to prepare RE 
with 80% CA from commercial available RE (with 45% CA). Moreover, their capacity to 
prevent metabolic disorders, such as obesity, hyperlipidemia, and hyperglycemia in different 
dosage was evaluated as well as their limit fat absorption mechanism. 
Rosemary is one of the most widely consumed spices worldwide. From its origin in 
Southeast Asia and its spread to Europe, rosemary is a well-known and greatly valued medicinal 
herb that is widely used in pharmaceutical products and folk medicine as a digestive, tonic, 
diuretic. More recently, it was reported that rosemary also possessed anticancer, antioxidant, 
antibacterial, and anti-inflammatory activities (Aljamal, 2012; Cheung, Hasman, Tai, & Wu, 
2012). However, there is less emphasis on the major responsible compound, effective dosage and 
underlying mechanisms of rosemary in management of metabolic diseases and their 
complications. Thus, it can be difficult to conclude the health benefits of a major component in 
RE to another exclusively on the basis of published data. This study has developed a new method 
to prepare CA and its enriched RE (80%), and evaluated their anti-obesity and anti-diabetic 
effects with different doses. 
5.1 Experiment 1- Preparation of CA and Its Enriched RE 
In this experiment, we prepared the CA enriched RE (80%) to identify the impact of CA 
and the dose effect of CA on weight gain, blood glucose and lipid hemostasis. There has been 
emergent interest in the employment of CA in food industry, for its usefulness as preservatives, 
as well as for its beneficial effects on human health (Song et al., 2014). CA, like any molecule of 
the catechol (or-tho-diphenol) type, is a reactive compound. It is highly sensitive to oxidation 
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and, hence, to all the operations typically carried out to isolate natural substances (extraction, 
liquid- liquid separation, chromatographic fraction, etc.) (Khalafi, Rafiee, Shahbak, & 
Shirmohammadi, 2013). This characterization of CA during its purification makes it an 
expensive component (85$/10 mg from Sigma). The problem addressed by the present 
experiment is to provide a process for enriching RE with 80% CA which would be economical 
and practical for the current study. 
5.2 Experiment 2- Study of the Effect of RE Enriched With CA on Body Weight Gain and 
Development of Metabolic Syndrome in HFD Treated C57BL/6J Mice 
5.2.1 Long term HFD induces obesity and related metabolic syndrome in the 
C57BL/6J mice. In animal studies which demonstrate metabolic syndromes to explore 
antiobesity and antidiabetes treatments, the choice of the animal model, diet, and experiment’s 
duration are critical points that need to be considered. In the present study we investigated the 
effects of the daily consumption of a HFD (60 Kcal % fat) on the development of obesity and 
related metabolic syndrome in C57BL/6J mice for 16-week. The results demonstrated that the 
HFD caused remarkably increased weight gain, fat accumulation, hyperglycemia, insulin 
resistance, and increased liver fat in our animal model. In contrast to the most previous similar 
studies dietary induced metabolic disorders models, the C57BL/6J mice phenotype becomes 
visible within 3 weeks of starting the HFD. 
5.2.2 CA is the major active component in RE. Our data indicate treatment of mice 
with 0.5 % w/w RE with 45% CA (~224 mg/Kg BW/day) reduced the gains in weight that were 
induced by the HFD, which are only 17.8 and 13.1% more than weight gain in LFD group. It 
also significantly lowered total fat tissue weight, hepatic TG, liver weight, fasting plasma insulin, 
fasting blood glucose compared with HFD mice. In addition, total fecal lipid content increased 
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significantly in RE#1 mice compared with the HFD group. Based on the present study, there was 
not any significant difference between the results from RE#1 and RE#2H (~225 mg/Kg 
BW/day). Since the quantities of CA contents were equal in these two groups, it appears that the 
CA plays an important role against in the metabolic disorders and is the major active compound 
in RE. Although various biological activities with preventive nutritional intervention against 
metabolic disorders has been developed for RE; nevertheless, the chemical description of applied 
extracts in studies, is not always available. Thus, it can be difficult to conclude the health 
benefits of a unique compound in RE on the basis of published data. Few studies have been 
conducted on CA as an effective compound in rosemary (Ninomiya et al., 2004; T. Wang et al., 
2011). Ninomiya et al. have observed that after 2-week of treatment with 20 mpk of CA alone, 
the weight of ddY (Deutschland,Derker, Yoker) mice fell by 7.6% compared with the control 
group (HFD 40% w/w fat) and the similar results demonstrated by Wang et al., whereas no 
results for fasting blood glucose effect has been observed in both studies. Our results together 
with the published data on CA in different animal models indicate that CA is the major active 
component in RE for obesity and related metabolic syndrome. 
5.2.3 Dose dependent effects of CA enriched RE. The results presented in Chapters 4 
show that RE with 80% CA could dose dependently reduce HFD induced obesity and metabolic 
syndrome by decreasing weight gain, fat mass accumulation, insulin resistance, and 
hypercholesterolemia. Furthermore, total fecal lipid content increased in groups with RE with 
80% CA dose dependently, compared with the HFD group. Based on the present study and other 
evidences (Harach et al., 2010; Ibarra et al., 2011), limiting lipid absorption in the intestine is a 
possible mechanism by which CA prevents weight gain. 
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  In our study, for the first time, we demonstrated the dose-dependent effect of CA 
enriched RE on obesity and related metabolic syndrome in the HFD treated mouse model. At 
week 3, the RE treated mice began to experience significant reductions in weight gain. The mice 
in both RE#1 and RE#2H groups, which contained the same amount of  CA (0.22% of diet w/w), 
showed significantly less weight gain than those in the RE#2L group (0.11% of diet w/w) after 
14-week treatment. These results are consistent with findings from Ibarra and Harach (Harach et 
al., 2010; Ibarra et al., 2011). In addition to its effects on weight gain, our results also 
demonstrated that CA significantly reduced elevated cholesterol levels that were induced by the 
HFD. Furthermore, they found no difference in serum TG and insulin level between control and 
treatment group; when our results demonstrated the reduction in liver TG, serum cholesterol, and 
FFA in compare to HFD. These findings demonstrate that CA, due specifically to fat mass 
reduction, has anti-obesity effects in vivo. Moreover, in the present study, fasting glycaemia and 
plasma insulin level were reduced in animals in the treatment groups dose dependently compared 
with the HFD control group. There are limited studies that have evaluated the effect of rosemary 
on diabetes. Anti-hyperglycaemic effects can be induced by an ethanolic RE in the alloxan 
diabetic rat model (Bakirel et al., 2008), however, there was not any information about RE 
compound. 
5.2.4 Toxicity. In the present study, chronic consumption of the high and low doses (28% 
and 14% of diet w/w) of CA enriched RE for 16-week did not show any toxicity to the treated 
mice. In contrast, CA significantly reduced the ALT and AST levels that induced by the high-fat 
diet which have not been observed in other studies on CA. 
5.2.5 Mechanism of RE enriched with CA on obesity and metabolic syndrome. There 
are many mechanisms that have been suggested by previous studies for RE against obesity and 
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metabolic syndrome. Some of these studies have been accomplished in vitro such as pancreatic 
lipase inhibition (Ninomiya et al., 2004), peroxisome proliferators-activated receptor gamma 
(PPARγ) activation, and the differentiation of mouse pre-adipocytes into adipocytes prevention 
(Takahashi et al., 2009). Some in vivo studies have investigated the ability of rosemary to control 
weight gain and glycaemia (Harach et al., 2010; H. Wang et al., 2011). Vaquero et al. in 2012 
demonstrated RE (40% CA) significantly inhibited gastric lipase activity in the stomach, which 
may cause a moderate reduction of fat absorption (M. Romo Vaquero et al., 2012). Several 
studies have found that limit fat absorption is the key mechanism for RE to limit weight gain 
(Harach et al., 2010; Ibarra et al., 2011; Ninomiya et al., 2004). The present study further 
confirms this mechanism by observing the increase of fecal fat excretion in RE treated mice. 
  5.2.6 Future research. The present study and literature studies found that RE could 
prevent weight gain and metabolic syndrome induced by HFD treatment. However, it is unclear 
whether RE has treatment effect to obese mice. In addition, it is also worthwhile to study the 
detail mechanisms that RE limits fat absorption. Furthermore, whether RE has antiobesity effect 
in human is another topic of future research. 
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